EffRx Pharmaceuticals SA is proud to inform that the latest safety data on Binosto® were presented as a poster on Sunday, 10th of September 2017 at the American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting in Denver, Colorado, USA attended by more than 3,000 scientists from 70 countries.
Binosto®, the world’s first and only buffered soluble alendronate for the treatment of osteoporosis, was developed with the aim to capitalize on the excellent efficacy profile of alendronate sodium while improving gastrointestinal tolerability. Upper gastrointestinal side effects are known to be problematic with tablet forms of alendronate sodium as well as of other bisphosphonates.
The authors of the ASBMR publication concluded that Binosto is associated with a lower frequency of upper gastrointestinal side effects than reported for tablet forms of alendronate sodium.
“This is an important milestone for EffRx as the post-marketing safety data support our hypothesis that the unique Binosto properties have a positive impact on incidence of upper gastrointestinal side effects,” says Dr. Josef Hruska, the first author and Executive Medical Director at EffRx Pharmaceuticals. He further states, “The reduction of upper gastrointestinal side effects will potentially lead to increased adherence which in turn results in realizing full antifracture efficacy.”
The Abstract will be published by the Journal of Bone Mineral Research.
About EffRx Pharmaceuticals SA
EffRx Pharmaceuticals SA is a Swiss-based commercial-stage pharmaceutical company developing and commercializing prescription medications for specialty indications. Our lead commercialized product, Binosto® (buffered soluble alendronate 70 mg) is indicated for the treatment of osteoporosis and marketed in US, Europe and Asia. We strive to address true unmet medical needs and provide improved outcomes to patients with musculoskeletal, genitourinary and endocrine disorders.
Binosto® (alendronate 70 mg effervescent tablets) is the first and only buffered solution for the treatment of osteoporosis with proven antifracture efficacy. The buffered solution minimizes the possibility of exposing the esophagus (in case of reflux) and the stomach to acidified alendronate and thus reducing the risk of upper gastrointestinal toxicity.1,2 In the EU, Binosto® is approved for the treatment of postmenopausal osteoporosis. It is taken once a week as an easy-to-swallow, buffered solution with no risk of a tablet getting lodged in the esophagus. Binosto® has the potential to improve long-term patient adherence to therapy, thereby decreasing the risk of disabling fractures.
Please refer to the official Binosto® prescribing information and approved indications, contraindications, and warnings in your country.
- Hodges LA et al. Modulation of gastric pH by a buffered soluble effervescent formulation: A possible means of improving gastric tolerability of alendronate. International Journal of Pharmaceutics 2012;432:57-62.
- Binosto 70mg SPC. www.mhra.gov.uk; accessed 19.9.2017
Media Contact: Pamela Saredi, email@example.com